Target type: biologicalprocess
The progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells. [GOC:ascb_2009, GOC:dph, GOC:tb]
Neural retina development is a complex and intricate process that transforms a simple sheet of undifferentiated cells into the intricate structure of the retina, the light-sensitive layer of the eye. This process involves a series of precisely regulated events, including cell proliferation, differentiation, migration, and axon guidance, all orchestrated by intricate molecular signaling pathways.
The development of the retina begins during embryonic development with the formation of the optic vesicle, an outpouching of the diencephalon, the posterior part of the forebrain. This vesicle invaginates to form the optic cup, which consists of two layers: the outer layer, which will become the pigmented epithelium, and the inner layer, which will become the neural retina.
The neural retina is further subdivided into five main cell types: photoreceptor cells, which convert light into electrical signals; bipolar cells, which relay these signals to ganglion cells; ganglion cells, which send the signals to the brain via the optic nerve; horizontal cells, which modulate the signals between photoreceptors and bipolar cells; and amacrine cells, which refine the signals between bipolar and ganglion cells.
The development of these different cell types is a complex and highly orchestrated process. It begins with the expression of specific transcription factors, which activate the expression of genes that determine cell fate. These factors also regulate the expression of cell adhesion molecules, which guide the migration and positioning of cells within the retina.
As cells differentiate, they form specific connections with each other, forming the intricate circuitry of the retina. Photoreceptor cells extend axons to the inner nuclear layer, where they synapse with bipolar cells. Bipolar cells then extend axons to the ganglion cell layer, where they synapse with ganglion cells. The axons of ganglion cells then converge to form the optic nerve, which carries visual information to the brain.
The development of the retina is also influenced by environmental cues, including light. Light exposure plays a crucial role in the development of photoreceptor cells, including the formation of their light-sensitive outer segments. This process is regulated by a complex interplay of signaling pathways, including the rhodopsin pathway, which is activated by light.
In addition to these fundamental processes, several other factors influence retinal development, including the interaction between the retinal cells and the surrounding tissues, such as the choroid and sclera. The choroid provides blood supply and nutrients to the retina, while the sclera provides structural support.
Disruptions in any of these processes can lead to various retinal diseases, including retinitis pigmentosa, age-related macular degeneration, and glaucoma. Understanding the intricate mechanisms underlying neural retina development is crucial for developing effective treatments for these debilitating conditions.
In summary, neural retina development is a complex and fascinating process that involves a series of precisely regulated events, including cell proliferation, differentiation, migration, and axon guidance, all orchestrated by intricate molecular signaling pathways. This process gives rise to the complex and highly organized structure of the retina, enabling us to perceive the world around us.'
"
Protein | Definition | Taxonomy |
---|---|---|
Transcription activator BRG1 | A transcription activator BRG1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P51532] | Homo sapiens (human) |
Presenilin-1 | A presenilin-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P49768] | Homo sapiens (human) |
Caspase-2 | A caspase-2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P42575] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
spermine | polyazaalkane; tetramine | antioxidant; fundamental metabolite; immunosuppressive agent | |
tocopheroxy radical | tocopheroxy radical: RN given refers to radical ion (1+), (2R-(2R*(4R*,8R*)))-isomer; RN for cpd without isomeric designation not available 12/90 | tocopherol | |
7-amino-4-chloro-3-methoxy-2-benzopyran-1-one | isocoumarins | ||
isoquinoline-1,3,4-trione | isoquinoline-1,3,4-trione: structure in first source | ||
n-methylisatin | N-methylisatin: structure given in first source | ||
cetylpyridinium chloride anhydrous | cetylpyridinium chloride : A pyridinium salt that has N-hexadecylpyridinium as the cation and chloride as the anion. It has antiseptic properties and is used in solutions or lozenges for the treatment of minor infections of the mouth and throat. tserigel: according to first source contains polyvinylbutyral & cetylpyridinium chloride; UD only lists cetylpyridinium chloride as constituent | chloride salt; organic chloride salt | antiseptic drug; surfactant |
tarenflurbil | tarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein; | flurbiprofen | |
cholanic acid | 5beta-cholanic acids; cholanic acid | ||
t0901317 | T0901317: an LXRalpha and LXRbeta agonist | ||
acetyl-aspartyl-glutamyl-valyl-aspartal | Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7. acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor | tetrapeptide | protease inhibitor |
5-Nitroisatin | indoles | anticoronaviral agent | |
benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor. | carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester | EC 3.4.23.46 (memapsin 2) inhibitor |
sulindac sulfide | sulindac sulfide : An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity. sulindac sulfide: sulfated analog of indomethacin & inhibitor of prostaglandin synthesis in vitro; RN given refers to cpd without isomeric designation; structure given in first source | aryl sulfide; monocarboxylic acid; organofluorine compound | antineoplastic agent; apoptosis inducer; non-steroidal anti-inflammatory drug |
l 685458 | L 685458: a gamma-secretase inhibitor; structure in first source L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease. | carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic |
mk 0752 | |||
ly 450139 | peptide | ||
chf 5074 | 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid: a beta-amyloid(1-42) lowering agent; structure in first source | ||
ly 411575 | dibenzoazepine; difluorobenzene; lactam; secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor | |
4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid | sulfonamide | ||
begacestat | |||
e 2012 | |||
PF-00835231 | PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity. | aromatic ether; indolecarboxamide; L-leucine derivative; primary alcohol; pyrrolidin-2-ones; secondary carboxamide | anticoronaviral agent; drug metabolite; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor |
mrk 560 | MRK 560: a gamma-secretase inhibitor; MRK-560 is the (cis)-isomer; structure in first source | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
1, 3-di-(n-carboxybenzoyl-leucyl-leucyl)amino acetone | 1, 3-di-(N-carboxybenzoyl-leucyl-leucyl)amino acetone: structure in first source | ||
pf 3084014 | nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment. nirogacestat: an antineoplastic agent | ||
bms 708163 | BMS 708163: structure in first source | oxadiazole; ring assembly | |
ro 4929097 | dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound | EC 3.4.23.46 (memapsin 2) inhibitor | |
jnj 40418677 | |||
(r)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1h-pyrazolo(4,3-c)quinoline | (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline: gamma secretase inhibitor; structure in first source | ||
MK-8353 | MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. MK-8353: ERK inhibitor used in oncology | aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles | antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
pf-06687252 | PF-06687252: a SMARCA2/4 bromodomain inhibitor; structure in first source PFI-3 : An azabicycloalkane that is (1R,4R)-2,5-diazabicyclo[2.2.1]heptane which is substituted at position 2 by a 3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl group and at position 5 by a pyridin-2-yl group. It is a potent and selective inhibitor of polybromo 1 (Kd = 48 nM), SMARCA2 and SMARCA4 (Kd = 89 nM) bromodomains. | azabicycloalkane; enone; phenols; pyridines |